+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Balofloxacin Market - Global Forecast to 2030- Product Image
Balofloxacin Market - Global Forecast to 2030- Product Image
New

Balofloxacin Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6082472
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Balofloxacin Market grew from USD 345.21 million in 2024 to USD 366.08 million in 2025. It is expected to continue growing at a CAGR of 5.76%, reaching USD 483.28 million by 2030.

In an era marked by the accelerating threat of antimicrobial resistance and evolving patient needs, Balofloxacin emerges as a critical agent within the fluoroquinolone class. This executive summary explores the multifaceted dynamics that define the current balofloxacin landscape, from shifting regulatory frameworks to the influence of global trade policies. As decision-makers and clinical experts seek robust intelligence to inform strategic planning, our analysis delves into the therapeutic advantages, application breadth, and innovation drivers that position balofloxacin as a frontline therapy for bacterial infections. We begin by outlining the context in which this antibiotic operates, setting the stage for a nuanced examination of market catalysts, barriers, and opportunities. Through a cohesive narrative, we draw attention to the pivotal factors shaping demand, adoption, and competitive positioning, guiding stakeholders toward informed, evidence-based actions.

Transformative Shifts Redefining the Antibacterial Market

The landscape of antibacterial therapies has undergone transformative shifts driven by scientific breakthroughs, patient-centric care models, and tightening regulatory scrutiny. Key drivers include the integration of precision dosing guided by pharmacokinetic/pharmacodynamic modeling, which optimizes therapeutic efficacy while mitigating adverse events. Concurrently, the rise of combination therapies and novel delivery platforms has reshaped formulary preferences, compelling manufacturers to innovate across oral, parenteral, and topical modes of administration. In parallel, health systems have adopted value-based procurement strategies, rewarding treatments that demonstrate clear clinical and economic benefits. These trends have elevated the importance of robust antimicrobial stewardship programs, which now serve as critical gatekeepers for prescribing patterns. As a result, balofloxacin must navigate an environment that demands both clinical superiority and cost-effectiveness. Understanding these transformative shifts is essential for mapping the pathways through which balofloxacin can achieve sustained market growth amidst an ever-more complex therapeutic ecosystem.

Cumulative Impact of 2025 U.S. Tariffs on Balofloxacin Supply Chains

The implementation of new United States tariffs in 2025 has introduced significant headwinds for pharmaceutical supply chains, particularly affecting raw materials and intermediate chemicals sourced from Asia-Pacific markets. Increased duties on key fluorinated intermediates have translated into a 5-10% rise in production costs for manufacturers utilizing overseas vendors. In response, several producers have accelerated their dual‐sourcing strategies, relocating portions of their synthesis capabilities to domestic or tariff‐exempt partner facilities. At the same time, downstream injection manufacturing and fill‐finish operations have experienced tighter margins, prompting a reevaluation of contract pricing frameworks and supplier agreements. While these measures preserve continuity of supply, they can also extend time‐to‐market for new dosage forms. In this context, strategic supply‐chain resilience and tariff mitigation efforts are paramount for maintaining competitive positioning and ensuring uninterrupted access to balofloxacin for patients in need.

Insights from Multifaceted Balofloxacin Market Segmentation

A granular segmentation of the balofloxacin market highlights distinct application, formulation, demographic, therapeutic, end-user, and administration dimensions that inform targeted strategies. For instance, gastrointestinal uses span bacterial gastroenteritis, Helicobacter pylori infections, and traveler’s diarrhea-each with unique resistance profiles and prophylactic considerations-while respiratory treatments encompass chronic bronchitis exacerbations and community-acquired pneumonia. Skin and soft tissue interventions address both cellulitis and wound infections, and urinary tract indications range from acute cystitis to complicated UTIs and pyelonephritis. From a formulation lens, balofloxacin is delivered via intramuscular and intravenous injections, along with coated, extended-release, and immediate-release tablets, oral suspensions, and topical solutions. Patient segmentation ranges broadly across adults (18-50 and over 50 years), geriatrics, children, and infant populations. As a fluoroquinolone antibiotic, balofloxacin navigates competitive pressures and formulary positioning within hospital, clinic, pharmacy, and research institute settings-each with private and public hospital distinctions. Oral, parenteral, and topical administration modes further shape product development priorities and market access pathways. Recognizing these multiple axes of segmentation is crucial for prioritizing investment and optimizing resource allocation.

Key Regional Dynamics Shaping Market Access and Growth

Regional dynamics are pivotal in shaping balofloxacin adoption and commercialization strategies. In the Americas, established regulatory frameworks and advanced antimicrobial stewardship programs drive premium pricing and foster early uptake of novel formulations. Conversely, Europe, the Middle East & Africa exhibit a heterogeneous patchwork of reimbursement policies and resistance trends, necessitating adaptive pricing models and localized clinical evidence generation. Meanwhile, Asia-Pacific represents a dual market of high-growth emerging economies and mature markets with stringent quality standards; here, partnerships with local manufacturing hubs and investment in pharmacovigilance infrastructure are key to capturing market share. Understanding these regional nuances enables stakeholders to tailor launch sequences, align supply‐chain logistics, and deploy targeted medical affairs initiatives that resonate with diverse healthcare environments.

Competitive Landscape and Leading Organizations in the Balofloxacin Ecosystem

An examination of leading organizations reveals a competitive landscape characterized by both large‐scale pharma incumbents and agile specialty producers. Established companies such as Merck & Co., Inc. and Thermo Fisher Scientific emphasize integrated R&D pipelines and global distribution networks, leveraging economies of scale to support broad formulary inclusion. At the same time, niche and contract research entities-including Ambeed, Inc., Biorbyt Ltd., Cambridge Bioscience Limited, and LGC Limited-focus on high-purity raw materials and analytical services, fueling upstream innovation. Emerging tech‐driven players like Patsnap, Inc. and Practo Technologies Pvt. Ltd. are revolutionizing drug discovery and market intelligence through AI‐enhanced platforms. Meanwhile, specialty chemical suppliers such as Key Organics Ltd, TCI Group, and ZellBio GmbH are expanding capacity to meet the surge in fluoroquinolone demand. Collectively, this diverse ecosystem underscores the importance of strategic alliances, vertical integration, and targeted acquisitions for sustaining a competitive edge in the balofloxacin market.

Actionable Recommendations for Balofloxacin Industry Leaders

Industry leaders can capitalize on the evolving balofloxacin market by pursuing a series of strategic actions. First, forging collaborative agreements with domestic and international suppliers will mitigate tariff exposure and secure uninterrupted access to key intermediates. Second, investing in pharmacovigilance studies and real‐world evidence generation will bolster formulary acceptance, particularly within value‐based care models. Third, advancing novel delivery systems-such as coated extended‐release tablets and topical formulations-can differentiate offerings and address unmet patient needs. Fourth, tailoring market access strategies to regional reimbursement frameworks will optimize launch sequencing and pricing. Fifth, leveraging digital health platforms to enhance physician engagement and adherence tracking will amplify market penetration. By systematically executing these recommendations, stakeholders can strengthen their competitive positioning and drive sustainable growth in a complex regulatory, clinical, and economic environment.

Conclusion and Strategic Synthesis of Market Insights

In sum, the balofloxacin market presents both challenges and opportunities across clinical, regulatory, and commercial dimensions. The interplay of antimicrobial stewardship imperatives, 2025 tariff pressures, and evolving patient demographics demands a multifaceted approach. Stakeholders must align supply-chain resilience, evidence generation, and tailored market access strategies to realize the full potential of balofloxacin as a critical therapeutic. By harnessing the insights outlined herein-from segmentation and regional dynamics to competitive intelligence-industry leaders are equipped to navigate uncertainties and drive impactful outcomes. This integrated perspective offers a roadmap for informed decision-making and sustainable portfolio growth.

Market Segmentation & Coverage

This research report categorizes the Balofloxacin Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Gastrointestinal Infections
    • Bacterial Gastroenteritis
    • Helicobacter Pylori Infections
    • Traveler's Diarrhea
      • Bacterial Strains Sensitivity
      • Prophylactic Usage
  • Respiratory Infections
    • Chronic Bronchitis Exacerbations
    • Community-Acquired Pneumonia
  • Skin And Soft Tissue Infections
    • Cellulitis
    • Wound Infections
  • Urinary Tract Infections
    • Acute Cystitis
    • Complicated UTIs
    • Pyelonephritis
  • Injection
    • Intramuscular
    • Intravenous
  • Oral Suspension
  • Tablet
    • Coated Tablets
    • Extended Release
    • Immediate Release
  • Topical
  • Adult
    • 18-50 Years
    • 50+ Years
  • Geriatric
  • Pediatric
    • Children
    • Infants
  • Antibiotic
  • Fluoroquinolone
  • Clinics
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Pharmacies
  • Research Institutes
  • Oral
  • Parenteral
  • Topical

This research report categorizes the Balofloxacin Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Balofloxacin Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Ambeed, Inc.
  • Apexbt Technology LLC.
  • B JOSHI AGROCHEM PHARMA
  • Biorbyt Ltd.
  • Biosynth Ltd.
  • BLDpharm
  • Cambridge Bioscience Limited
  • Chemodex Ltd.
  • Cymit Química S.L.
  • Glentham Life Sciences
  • Honeywell International Inc
  • JoinHub Pharma
  • Key Organics Ltd
  • LGC Limited
  • LKT Laboratories
  • Lupin Limited
  • Merck & Co., Inc.
  • Patsnap, Inc.
  • Practo Technologies Pvt. Ltd.
  • Santa Cruz Biotechnology, Inc.
  • TargetMol Chemicals Inc.
  • TCI Group
  • Thermo Fisher Scientific
  • ZellBio GmbH

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Balofloxacin Market, by Application
8.1. Introduction
8.2. Gastrointestinal Infections
8.2.1. Bacterial Gastroenteritis
8.2.2. Helicobacter Pylori Infections
8.2.3. Traveler's Diarrhea
8.2.3.1. Bacterial Strains Sensitivity
8.2.3.2. Prophylactic Usage
8.3. Respiratory Infections
8.3.1. Chronic Bronchitis Exacerbations
8.3.2. Community-Acquired Pneumonia
8.4. Skin And Soft Tissue Infections
8.4.1. Cellulitis
8.4.2. Wound Infections
8.5. Urinary Tract Infections
8.5.1. Acute Cystitis
8.5.2. Complicated UTIs
8.5.3. Pyelonephritis
9. Balofloxacin Market, by Drug Formulation
9.1. Introduction
9.2. Injection
9.2.1. Intramuscular
9.2.2. Intravenous
9.3. Oral Suspension
9.4. Tablet
9.4.1. Coated Tablets
9.4.2. Extended Release
9.4.3. Immediate Release
9.5. Topical
10. Balofloxacin Market, by Patient Demographics
10.1. Introduction
10.2. Adult
10.2.1. 18-50 Years
10.2.2. 50+ Years
10.3. Geriatric
10.4. Pediatric
10.4.1. Children
10.4.2. Infants
11. Balofloxacin Market, by Therapeutic Class
11.1. Introduction
11.2. Antibiotic
11.3. Fluoroquinolone
12. Balofloxacin Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Hospitals
12.3.1. Private Hospitals
12.3.2. Public Hospitals
12.4. Pharmacies
12.5. Research Institutes
13. Balofloxacin Market, by Mode Of Administration
13.1. Introduction
13.2. Oral
13.3. Parenteral
13.4. Topical
14. Americas Balofloxacin Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Balofloxacin Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Balofloxacin Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Ambeed, Inc.
17.3.2. Apexbt Technology LLC.
17.3.3. B JOSHI AGROCHEM PHARMA
17.3.4. Biorbyt Ltd.
17.3.5. Biosynth Ltd.
17.3.6. BLDpharm
17.3.7. Cambridge Bioscience Limited
17.3.8. Chemodex Ltd.
17.3.9. Cymit Química S.L.
17.3.10. Glentham Life Sciences
17.3.11. Honeywell International Inc
17.3.12. JoinHub Pharma
17.3.13. Key Organics Ltd
17.3.14. LGC Limited
17.3.15. LKT Laboratories
17.3.16. Lupin Limited
17.3.17. Merck & Co., Inc.
17.3.18. Patsnap, Inc.
17.3.19. Practo Technologies Pvt. Ltd.
17.3.20. Santa Cruz Biotechnology, Inc.
17.3.21. TargetMol Chemicals Inc.
17.3.22. TCI Group
17.3.23. Thermo Fisher Scientific
17.3.24. ZellBio GmbH
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BALOFLOXACIN MARKET MULTI-CURRENCY
FIGURE 2. BALOFLOXACIN MARKET MULTI-LANGUAGE
FIGURE 3. BALOFLOXACIN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BALOFLOXACIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BALOFLOXACIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BALOFLOXACIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BALOFLOXACIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BALOFLOXACIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS BALOFLOXACIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS BALOFLOXACIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES BALOFLOXACIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES BALOFLOXACIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BALOFLOXACIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BALOFLOXACIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. BALOFLOXACIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. BALOFLOXACIN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BALOFLOXACIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BALOFLOXACIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BALOFLOXACIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BALOFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BALOFLOXACIN MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BALOFLOXACIN MARKET SIZE, BY HELICOBACTER PYLORI INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BALOFLOXACIN MARKET SIZE, BY BACTERIAL STRAINS SENSITIVITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BALOFLOXACIN MARKET SIZE, BY PROPHYLACTIC USAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BALOFLOXACIN MARKET SIZE, BY CHRONIC BRONCHITIS EXACERBATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BALOFLOXACIN MARKET SIZE, BY COMMUNITY-ACQUIRED PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BALOFLOXACIN MARKET SIZE, BY CELLULITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BALOFLOXACIN MARKET SIZE, BY WOUND INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BALOFLOXACIN MARKET SIZE, BY ACUTE CYSTITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BALOFLOXACIN MARKET SIZE, BY COMPLICATED UTIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BALOFLOXACIN MARKET SIZE, BY PYELONEPHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BALOFLOXACIN MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BALOFLOXACIN MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BALOFLOXACIN MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BALOFLOXACIN MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BALOFLOXACIN MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BALOFLOXACIN MARKET SIZE, BY COATED TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BALOFLOXACIN MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BALOFLOXACIN MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BALOFLOXACIN MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BALOFLOXACIN MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BALOFLOXACIN MARKET SIZE, BY 18-50 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BALOFLOXACIN MARKET SIZE, BY 50+ YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BALOFLOXACIN MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BALOFLOXACIN MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BALOFLOXACIN MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BALOFLOXACIN MARKET SIZE, BY ANTIBIOTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BALOFLOXACIN MARKET SIZE, BY FLUOROQUINOLONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BALOFLOXACIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BALOFLOXACIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BALOFLOXACIN MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BALOFLOXACIN MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BALOFLOXACIN MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BALOFLOXACIN MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BALOFLOXACIN MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BALOFLOXACIN MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BALOFLOXACIN MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BALOFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. CANADA BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. CANADA BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 116. CANADA BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 117. CANADA BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 118. CANADA BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 119. CANADA BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 120. CANADA BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 121. CANADA BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 122. CANADA BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 123. CANADA BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 124. CANADA BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 125. CANADA BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 126. CANADA BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 127. CANADA BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. CANADA BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 129. CANADA BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. MEXICO BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. MEXICO BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 132. MEXICO BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 133. MEXICO BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 134. MEXICO BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 135. MEXICO BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 136. MEXICO BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 137. MEXICO BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 138. MEXICO BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 139. MEXICO BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 140. MEXICO BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 141. MEXICO BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 142. MEXICO BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 143. MEXICO BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. MEXICO BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 145. MEXICO BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES BALOFLOXACIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC BALOFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 185. AUSTRALIA BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. CHINA BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. CHINA BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 198. CHINA BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 199. CHINA BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 200. CHINA BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 201. CHINA BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 202. CHINA BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 203. CHINA BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 204. CHINA BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 205. CHINA BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 206. CHINA BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 207. CHINA BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 208. CHINA BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 209. CHINA BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. CHINA BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 211. CHINA BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. INDIA BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 213. INDIA BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 214. INDIA BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 215. INDIA BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 216. INDIA BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 217. INDIA BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 218. INDIA BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 219. INDIA BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 220. INDIA BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 221. INDIA BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 222. INDIA BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 223. INDIA BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 224. INDIA BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 225. INDIA BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. INDIA BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 227. INDIA BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. INDONESIA BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. INDONESIA BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 230. INDONESIA BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 231. INDONESIA BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 232. INDONESIA BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 233. INDONESIA BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 234. INDONESIA BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 235. INDONESIA BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 236. INDONESIA BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 237. INDONESIA BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 238. INDONESIA BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. JAPAN BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. JAPAN BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 246. JAPAN BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 247. JAPAN BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 248. JAPAN BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 249. JAPAN BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 250. JAPAN BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 251. JAPAN BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 252. JAPAN BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 253. JAPAN BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 254. JAPAN BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 255. JAPAN BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 256. JAPAN BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 257. JAPAN BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. JAPAN BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 259. JAPAN BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. MALAYSIA BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. MALAYSIA BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 263. MALAYSIA BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 265. MALAYSIA BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 266. MALAYSIA BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 267. MALAYSIA BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 268. MALAYSIA BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 269. MALAYSIA BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 270. MALAYSIA BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 271. MALAYSIA BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 272. MALAYSIA BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 273. MALAYSIA BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. MALAYSIA BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 275. MALAYSIA BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. PHILIPPINES BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 277. PHILIPPINES BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 278. PHILIPPINES BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 279. PHILIPPINES BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 280. PHILIPPINES BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 281. PHILIPPINES BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 282. PHILIPPINES BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 283. PHILIPPINES BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 284. PHILIPPINES BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 285. PHILIPPINES BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 286. PHILIPPINES BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 287. PHILIPPINES BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. SINGAPORE BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 293. SINGAPORE BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 294. SINGAPORE BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 295. SINGAPORE BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 296. SINGAPORE BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 297. SINGAPORE BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 298. SINGAPORE BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 299. SINGAPORE BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 300. SINGAPORE BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 301. SINGAPORE BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 302. SINGAPORE BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 303. SINGAPORE BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 304. SINGAPORE BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 305. SINGAPORE BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. SINGAPORE BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 307. SINGAPORE BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 315. SOUTH KOREA BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 316. SOUTH KOREA BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 317. SOUTH KOREA BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 318. SOUTH KOREA BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 319. SOUTH KOREA BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 320. SOUTH KOREA BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 321. SOUTH KOREA BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 322. SOUTH KOREA BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 323. SOUTH KOREA BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. TAIWAN BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 325. TAIWAN BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 326. TAIWAN BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 327. TAIWAN BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 328. TAIWAN BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 329. TAIWAN BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 330. TAIWAN BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 331. TAIWAN BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 332. TAIWAN BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 333. TAIWAN BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 334. TAIWAN BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 335. TAIWAN BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 336. TAIWAN BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 337. TAIWAN BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 338. TAIWAN BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 339. TAIWAN BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 340. THAILAND BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 341. THAILAND BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 342. THAILAND BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 343. THAILAND BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 344. THAILAND BALOFLOXACIN MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, 2018-2030 (USD MILLION)
TABLE 345. THAILAND BALOFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 346. THAILAND BALOFLOXACIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 347. THAILAND BALOFLOXACIN MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 348. THAILAND BALOFLOXACIN MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 349. THAILAND BALOFLOXACIN MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 350. THAILAND BALOFLOXACIN MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 351. THAILAND BALOFLOXACIN MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 352. THAILAND BALOFLOXACIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 353. THAILAND BALOFLOXACIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 354. THAILAND BALOFLOXACIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 355. THAILAND BALOFLOXACIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 356. VIETNAM BALOFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 357. VIETNAM BALOFLOXACIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 358. VIETNAM BALOFLOXACIN MARKET SIZE, BY TRAVELER'S DIARRHEA, 2018-2030 (USD MILLION)
TABLE 359. VIETNAM BALOFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABL

Companies Mentioned

  • Ambeed, Inc.
  • Apexbt Technology LLC.
  • B JOSHI AGROCHEM PHARMA
  • Biorbyt Ltd.
  • Biosynth Ltd.
  • BLDpharm
  • Cambridge Bioscience Limited
  • Chemodex Ltd.
  • Cymit Química S.L.
  • Glentham Life Sciences
  • Honeywell International Inc
  • JoinHub Pharma
  • Key Organics Ltd
  • LGC Limited
  • LKT Laboratories
  • Lupin Limited
  • Merck & Co., Inc.
  • Patsnap, Inc.
  • Practo Technologies Pvt. Ltd.
  • Santa Cruz Biotechnology, Inc.
  • TargetMol Chemicals Inc.
  • TCI Group
  • Thermo Fisher Scientific
  • ZellBio GmbH

Methodology

Loading
LOADING...

Related Topics

Related Reports

Balofloxacin (CAS 127294-70-6) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Balofloxacin (CAS 127294-70-6) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Cefaclor Market by Type, Spectrum Activity, Formulation, Application - Global Forecast 2025-2030 - Product Image

Cefaclor Market by Type, Spectrum Activity, Formulation, Application - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Peptide Antibiotics Market Size, Share & Trends Analysis Report By Disease (Skin Infection, HABP/VABP), By Route of Administration (Injectable, Oral), By Product, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Peptide Antibiotics Market Size, Share & Trends Analysis Report By Disease (Skin Infection, HABP/VABP), By Route of Administration (Injectable, Oral), By Product, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Cephalosporin Market Report by Generation, Route of Administration, Application, and Region ?2025-2033 - Product Image

Cephalosporin Market Report by Generation, Route of Administration, Application, and Region ?2025-2033

  • Report
  • 144 Pages
  • Global
From

About the Balofloxacin Market

Balofloxacin is an antibiotic used to treat a variety of bacterial infections. It belongs to the fluoroquinolone class of antibiotics, which are used to treat a wide range of bacterial infections. Balofloxacin is used to treat infections of the respiratory tract, urinary tract, skin, and soft tissue. It is also used to treat certain sexually transmitted diseases. Balofloxacin is generally well tolerated, but can cause side effects such as nausea, vomiting, and diarrhea. The market for balofloxacin is driven by the increasing prevalence of bacterial infections, as well as the increasing demand for antibiotics. The rising prevalence of antibiotic-resistant bacteria is also driving the market for balofloxacin. The increasing demand for balofloxacin in developing countries is also contributing to the growth of the market. Some of the major companies in the balofloxacin market include Pfizer, Merck, GlaxoSmithKline, Sanofi, AstraZeneca, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.